Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15:288–98.

Article  PubMed  Google Scholar 

Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, et al. Obesity in adults: a clinical practice guideline. C. Can Med Assoc J. 2020;192:E875–91.

Article  Google Scholar 

Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine. 2023;58:101882.

Article  PubMed  PubMed Central  Google Scholar 

Christoffersen BØ, Sanchez-Delgado G, John LM, Ryan DH, Raun K, Ravussin E. Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss. Obesity. 2022;30:841–57.

Article  PubMed  Google Scholar 

Mathiesen DS, Lund A, Vilsbøll T, Knop FK, Bagger JI. Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat. Front Endocrinol. 2020;11:617400.

Article  Google Scholar 

Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI insight. 2020;5:e133429.

Article  PubMed  PubMed Central  Google Scholar 

Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402:705–19.

Article  CAS  PubMed  Google Scholar 

Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389:514–26.

Article  CAS  PubMed  Google Scholar 

Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398:2160–72.

Article  CAS  PubMed  Google Scholar 

Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397:1736–48.

Article  CAS  PubMed  Google Scholar 

Andreassen KV, Larsen AT, Sonne N, Mohamed KE, Karsdal MA, Henriksen K. KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats. Mol Metab. 2021;53:101282.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Larsen AT, Mohamed KE, Sonne N, Bredtoft E, Andersen F, Karsdal MA, et al. Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models. Biomed Pharmacother. 2022;156:113842.

Article  CAS  PubMed  Google Scholar 

Gydesen S, Andreassen KV, Hjuler ST, Christensen JM, Karsdal MA, Henriksen K. KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight. Am J Physiol Endocrinol Metab. 2016;310:E821–7.

Article  PubMed  Google Scholar 

Larsen AT, Sonne N, Andreassen KV, Gehring K, Karsdal MA, Henriksen K. The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy. J Pharm Exp Ther. 2019;370:35–43.

Article  CAS  Google Scholar 

Larsen AT, Sonne N, Andreassen KV, Karsdal MA, Henriksen K. The Calcitonin Receptor Plays a Major Role in Glucose Regulation as a Function of Dual Amylin and Calcitonin Receptor Agonist Therapy. J Pharm Exp Ther. 2020;374:74–83.

Article  CAS  Google Scholar 

Hjuler ST, Gydesen S, Andreassen KV, Pedersen SLK, Hellgren LI, Karsdal MA, et al. The dual amylin- and calcitonin-receptor agonist KBP-042 increases insulin sensitivity and induces weight loss in rats with obesity. Obesity. 2016;24:1712–22.

Article  CAS  PubMed  Google Scholar 

Gydesen S, Hjuler ST, Freving Z, Andreassen KV, Sonne N, Hellgren LI, et al. A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference. Br J Pharm. 2017;174:591–602.

Article  CAS  Google Scholar 

Avram VF, Merce AP, Hâncu IM, Bătrân AD, Kennedy G, Rosca MG, et al. Impairment of Mitochondrial Respiration in Metabolic Diseases: An Overview. Int J Mol Sci. 2022;23:8852.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prasun P. Mitochondrial dysfunction in metabolic syndrome. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165838.

Article  CAS  PubMed  Google Scholar 

Brand MD, Orr AL, Perevoshchikova IV, Quinlan CL. The role of mitochondrial function and cellular bioenergetics in ageing and disease. Br J Dermatol. 2013;169:1–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pfeifer A, Hoffmann LS. Brown, beige, and white: the new color code of fat and its pharmacological implications. Annu Rev Pharm Toxicol. 2015;55:207–27.

Article  CAS  Google Scholar 

Cai J, Wang F, Shao M. The Emerging Importance of Mitochondria in White Adipocytes: Neither Last nor Least. Endocrinol Metab. 2023;38:493–503.

Article  CAS  Google Scholar 

Lee JH, Park A, Oh K-J, Lee SC, Kim WK, Bae K-H. The Role of Adipose Tissue Mitochondria: Regulation of Mitochondrial Function for the Treatment of Metabolic Diseases. Int J Mol Sci. 2019;20:4924.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heinonen S, Jokinen R, Rissanen A, Pietiläinen KH. White adipose tissue mitochondrial metabolism in health and in obesity. Obes Rev J Int Assoc Study Obes. 2020;21:e12958.

Article  Google Scholar 

Thorsø Larsen A, Karsdal MA, Henriksen K. Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss. Eur J Pharm. 2023;954:175837.

Article  Google Scholar 

Larsen S, Danielsen JH, Søndergård SD, Søgaard D, Vigelsoe A, Dybboe R, et al. The effect of high-intensity training onmitochondrial fat oxidation in skeletal muscle and subcutaneous adipose tissue. Scand J Med Sci Sports. 2015;25:59–69.

Article  Google Scholar 

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–8.

Article  CAS  PubMed  Google Scholar 

Schmidt SF, Madsen JGS, Frafjord KØ, Poulsen LL, Salö S, Boergesen M, et al. Integrative Genomics Outlines a Biphasic Glucose Response and a ChREBP-RORγ Axis Regulating Proliferation in β Cells. Cell Rep. 2016;16:2359–72.

Article  CAS  PubMed  Google Scholar 

Sutherland LN, Capozzi LC, Turchinsky NJ, Bell RC, Wright DC. Time course of high-fat diet-induced reductions in adipose tissue mitochondrial proteins: potential mechanisms and the relationship to glucose intolerance. Am J Physiol Endocrinol Metab. 2008;295:E1076–83.

Article  CAS  PubMed  Google Scholar 

Kraunsøe R, Boushel R, Hansen CN, Schjerling P, Qvortrup K, Støckel M, et al. Mitochondrial respiration in subcutaneous and visceral adipose tissue from patients with morbid obesity. J Physiol. 2010;588:2023–32.

Article  PubMed  PubMed Central  Google Scholar 

Thrush AB, Dent R, McPherson R, Harper M-E. Implications of mitochondrial uncoupling in skeletal muscle in the development and treatment of obesity. FEBS J. 2013;280:5015–29.

Article  CAS  PubMed  Google Scholar 

Mack C, Wilson J, Athanacio J, Reynolds J, Laugero K, Guss S, et al. Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight. Am J Physiol Regul Integr Comp Physiol. 2007;293:R1855–63.

Article